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Purpose: To examine the effects of a histone deacetylase inhibitor, Trichostatin A (TSA), on the behavior of macrophages
and subconjunctival fibroblasts in vitro and on ocular surface inflammation and scarring in vivo using an alkali burn
wound healing model.
Methods: Effects of TSA on expression of inflammation-related growth factors or collagen I were examined by real-time
RT–PCR or immunoassay in mouse macrophages or human subconjunctival fibroblasts. Effects of TSA on trans forming
growth factor β (TGFβ)/Smad signaling were evaluated with western blotting and/or immunocytochemistry. Alkali-burn
injuries on the eyes of mice were performed with three µl of 0.5 N NaOH under general and topical anesthesia. TSA (600
µg/Kg daily) or vehicle was administered to animals via intraperitoneal (i.p.) injection. Histology and real-time RT–PCR
investigations evaluated the effects of TSA on the healing process of the cornea.
Results: TSA inhibited TGFβ 1 and vascular endothelial growth factor (VEGF) expression in macrophages, and TGFβ1
and collagen I in ocular fibroblasts. It elevated the expression of 5′-TG-3′-interacting factor (TGIF) and Smad7 in
fibroblasts and blocked nuclear translocation of phospho-Smad2. Real-time PCR and immunocytochemistry studies
showed that systemic administration of TSA suppressed the inflammation and fibrotic response in the stroma and
accelerated epithelial healing in the alkali-burned mouse cornea.
Conclusions: Systemic administration of TSA reduces inflammatory and fibrotic responses in the alkali-burned mouse
ocular surface in vivo. The mechanisms of action involve attenuation of Smad signal in mesenchymal cells and reduction
in the activation and recruitment of macrophages. TSA has the potential to treat corneal scarring in vivo.
Fibroblasts and macrophages induce inflammatory and/
or  fibrogenic  disorders  in  various  tissues  by  expressing
profibrogenic cytokines and/or extracellular matrix (ECM)
components [1]. Pro-inflammatory cytokines expressed by
these cell types are a further chemoattractant to inflammatory
cells. Among ocular surface fibrogenic diseases, alkali burn,
vernal  or  atopic  conjunctivitis,  and  Stevens-Johnson’s
syndrome are common [1,2]. Inflammatory reaction in the
ocular surface causes activation of subconjunctival fibroblasts
followed  by  fibrogenic  sequealae  and  potentially  leads  to
visual impairment by damaging the ocular surface.
The profibrogenic phenotype of tissue mesenchymal cell
types could be modulated by a combination of epigenetic
alterations such as methylation and (de)acetylation which are
reversible, and offer a potential opportunity to reverse the
epigenetic  pattern  [3,4].  In  normal  resting  cells,  DNA  is
organized  within  nucleosomes  in  chromatin  and  proteins,
histones,  that  regulate  the  level  of  gene  transcription  [5].
Histone  hyperacetylation  generally  promotes  gene
transcription. Deacetylation of histones mediated by histone
deacetylases (HDACs) causes wrapping of the DNA around
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the  nucleosome  and  prevents  transcription  factors  from
binding to it [6]. HDACs are enzyme complexes that remove
the acetyl group from the histones [7]. Trichostatin A (TSA,
m.w.=302.4) is a potent reversible HDAC inhibitor [8]. TSA
has been tested in clinical trials for cancer therapy based on
its  effect  of  cell  cycle  arrest  [9-11]  and  also  has  been
considered a potential therapeutic agent against fibrogenic
diseases  likes  hepatic  fibrosis  and  cutaneous  radiation
syndrome  [12-15].  Although  the  mechanism  is  not  fully
understood, it might include suppression of Smad-mediated
gene expression by TSA. In ocular surface tissues (cornea or
conjunctiva),  we  recently  reported  that  TSA  suppresses
myofibroblast generation, one of the hallmarks of fibrosis, in
cultured keratocytes and significantly reduces stromal haze in
the  rabbit  cornea  following  excimer  laser  injury  [16].
However, effects of systemic administration of a TSA on
inflammation-related  fibrogenic  reaction  in  the  ocular
surface,  and  its  effects  on  pro-inflammatory  cytokine
expression in the macropahges, and on signal transduction in
ocular fibroblasts have not yet been investigated.
In the present study, we tested the effects of TSA on (i)
fibrogenic behavior i.e., proliferation, migration, expression
of  fibrogenic  mediators,  etc.;  (ii)  signal  transduction  of
cultured  human  subconjunctival  fibroblasts;  and  (iii)
inflammatory reaction in cultured macrophages. Furthermore,
we investigated whether systemic administration of TSA has
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2964a therapeutic effect on ocular surface fibrosis using an alkali-
burn mouse model. The goal of the current study was to
evaluate the therapeutic potential of TSA in patients with
ocular surface inflammatory fibrogenic diseases of the ocular
surface.
METHODS
Primary  subconjunctival  fibroblast  culture:  Human
subconjunctival  fibroblasts  were  cultured  as  described
previously [17]. In brief, subconjunctival tissue was obtained
during strabismus surgery with informed consent from the
patients’ parents. The cells were cultured for 2 or 3 passages
in Eagle’s minimum essential medium (MEM; Gibco, Grand
Island, NY) supplemented with antibiotics, an antimycotic,
and 10% fetal calf serum (MEM-10) before the following
experiments. A stock solution of TSA (Sigma, St. Louis, MO)
at a concentration of 2 M [18] was prepared in ethanol and
stored at −80 °C. The final concentration of ethanol in the
medium was 0.06%.
Cell migration: Cell migration was examined by scratch assay
as reported previously [19]. In brief, closure of a liner defect
produced  in  the  cell  monolayer  was  determined  in  the
presence or absence of TSA (10, 200, and 500 nM) at 36 h
post scratching.
Quantification of mRNA by real-time PCR: Confluent ocular
surface  fibroblasts  in  a  60-mm  tissue  culture  dish  were
generated and incubated for 24 h in the presence or absence
of various concentrations of TSA in serum-free medium. Total
RNA was extracted using a Mammalian Total RNA Miniprep
Kit (Sigma, St. Louis, MO) as reported earlier [19,20]. The
expression of transforming growth factor β1 (TGFβ1) and
collagen Iα1 mRNA was determined with real-time RT-PCR
using appropriate TaqMan probes (Applied Biosystems). As
for this probe, forward primer and reverse primer were already
done premixing of. The real-time RT-PCR method using the
Taqman One-Step RT-PCR Master Mix Reagents Kit and the
Applied Biosystems Prism 7300 (P-E Applied Biosystems,
Foster City, CA) was employed. The RT-PCR conditions
were  as  follows:  30  min  at  48  °C  (stage  1,  reverse
transcription), 10 min at 95 °C (stage 2, reverse transcription
inactivation  and  AmpliTaq  Gold  activation),  and  then  40
cycles of amplification for 15 s at 95 °C and 1 min at 60 °C
(stage 3, polymerase chain reaction).
ELISA assay: ELISA assays were performed to determine the
expression  TGFβ1  and  fibronectin  protein  levels  in
subconjunctival fibroblasts using an ELISA kit purchased
from R&D Systems (Minneapolis, MN). Cultures grown in a
24-well culture dish were incubated in the presence or absence
of TSA in 1 ml serum-free medium for 48 h. Culture medium
was harvested, and stored at −80 °C. The protein levels in
samples were measured with an ELISA kit following the
manufacturer’s instructions as described previously [21,22].
We evaluated protein levels after having reacted reagent and
samples by measuring absorbance.
Immunocytochemistry: The cells (1.8×103 in 300 µl medium/
well) were grown to subconfluency in each well of 8-well
Nunc Lab-Tec chamber slides (Nunc, Rochester, NY) and
then grown in the presence or absence of TSA in serum-free
medium for 24 h. The cultures were washed and fixed with
cold acetone. Immunohistochemistry for collagen type I and
fibronectin (EDA domain) protein was performed using goat
polyclonal anti-collagen I (1:100 dilution in PBS; Southern
Biotechnology, Birmingham, AL) and goat polyclonal anti-
fibronectin (1:100 dilution in PBS; Santa Cruz Biotechnology,
Santa Cruz, CA) antibodies, respectively, followed by the
incubation  with  FITC-conjugated  secondary  antibodies
(1:100 dilution in PBS; ICN Biomedicals, Aurora, OH) and
nuclear  staining  with  DAPI  dye  following  the  method
reported  earlier  [19,20,23].  The  specimens  were  observed
under fluorescent microscopy.
Effects of TSA on cell signal transduction: The effects of TSA
on TGFβ1/Smad signaling were evaluated using western blot
and  immunocytochemistry  techniques.  For  western  blot
analysis,  subconjunctival  fibroblasts  were  grown  to
confluence in 60-mm culture dishes, and then treated with
various  concentrations  (up  to  500  nM)  of  TSA  for  24  h.
Cultures were then exposed to exogenous TGFβ1 for 1 or 2 h,
harvested in Sigma Mammalian Cell Lysis buffer (100 µl/
dish, Sigma-Aldrich, St. Louis, MO), and subjected to SDS–
PAGE  and  western  blotting  [24].  Polyclonal  primary
antibodies  against  phospho-Smad2  (pSmad2;  Chemicon
International,  Temecula,  CA),  Smad2  (Santa  Cruz
Biotechnology), TGIF (Santa Cruz), Smad7 (Santa Cruz), and
β-actin (Santa Cruz) were used. Smad2 is a TGFβ signal
transducer and is activated by phosphorylation. Smad7 is an
inhibitory  Smad  that  blocks  phosphorylation  and  nuclear
translocation of Smads2/3. TGIF is also a negative regulator
of TGFβ/Smad signal.
For immunocytochemistry, subconjunctival fibroblasts
(4.0×103/well  in  300  µl  medium)  were  grown  to
subconfluence  in  8-well  Nunc  Lab-Tec  chamber  slides.,
Cultures were grown in the presence or absence of TSA in
serum-free medium for 6 h after growing them in MEM-10
for 24 h. Then, cultures were treated with TGF β 1 (1.0 ng/ml,
R&D Systems) for 0.5, 1, or 2 h. Samples were washed, fixed
with  4%  paraformaldehyde,  and  processed  for
immunocytochemistry for phosphorylated Smad2 (pSmad2)
using anti-phospho-Smad2 antibody (Chemicon) [25].
Primary  macrophage  culture:  Mouse  macrophages  were
obtained  from  the  peritoneal  space  using  a  glycogen
stimulation method as previously reported [19]. In brief, 5%
sterilized oysterglycogen (Sigma-Aldrich) was injected into
the peritoneal space of mice. After 4 days, the peritoneal
cavity  was  irrigated  with  culture  medium  to  harvest
macrophages. About 90% of cells were positive for F4/80.
F4/80 is a transmembrane protein present on the cell-surface
of  mouse  macrophages.  Markers  of  mouse  macrophage
Molecular Vision 2010; 16:2964-2973 <http://www.molvis.org/molvis/v16/a319> © 2010 Molecular Vision
2965development  detected  by  moncolonal  antibodies.  The
expression of TGFβ1 and VEGF mRNA was determined with
real-time  RT-PCR  using  appropriate  TaqMan  probes
(Applied Biosystems) as reported earlier [20].
In vitro neovascularization: A commercial kit containing an
in  vitro  co-culture  system  of  human  vascular  endothelial
(HUVECs) and fibroblast cells was used according to the
manufacturer’s instructions (NV kit; Kurabo, Tokyo, Japan).
This  system  co-cultures  vascular  endothelial  cells  on  a
fibroblast feeder layer and is used to evaluate new vessel
formation  based  on  increases  in  CD31-positive  tube-like
tissue formation. The effect was determined by adding TSA
(10, 20, and 500 nM) on VEGF-A (10 ng/ml; Kurabo, Tokyo,
Japan) stimulated vessel-like tube formation according to the
protocol provided by the manufacturer. Tube-like tissue was
detected by immunostaining for CD31, an endothelial cell
marker  at  day  11  of  culture.  Color  development  was
performed  by  diaminobenzidine  (DAB)  color  reaction  as
reported  [19].  Five  wells  were  prepared  for  each  culture
condition. The length and number of branch points and the
mean  value  was  determined  in  three  different  300  mm2
regions.
Effect of TSA on ocular surface inflammation and fibrosis in
an  alkali-burn  mouse  model:  We  finally  examined  the
therapeutic effects of systemic administration of TSA on the
ocular  surface  fibrosis  induced  in  mice  by  the  topical
application of 0.5N NaOH. The study was approved by the
Institutional Animal Care and Use Committee, and animals
were  treated  in  accordance  with  the  tenets  of  the  ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research. NaOH solution (3 µl of a 0.5N stock) was topically
applied onto the eye of adult C57BL/6 mice (n=44) under
general  (ketamine  hydrochloride  40  mg/kg  and  xylazine
hydrochloride 5 mg/kg from Sigma) and topical (1 drop of
proparacaine hydrochloride 0.5% from Bausch and Lomb,
Pharmaceuticals, Inc. Tampa, FL) anesthesia 24 h after i.p.
injection of TSA (600 µg/kg, n=22) or vehicle (n=22). The
mice continued to receive TSA (600 µg/kg) or vehicle through
i.p. injection until euthanasia. The TSA-treated and control
animals were sacrificed either on day-5 (n=12) or day-10
(n=10) after imaging the eyes. The eyes were fixed in 4%
paraformaldehyde and processed for paraffin sections.
Immunohistochemistry was conducted using antibodies
against ”α smooth muscle actin (αSMA), F4/80, or collagen
IV  (α1chain;  a  polyclonal  antibody  from  Southern
Biotechnology, Temecula, CA) as previously reported [25,
26].
Another set of similar experiments with TSA (n=20) and
control  (n=20)  was  performed  to  evaluate  αSMA
(myofibroblast appearance), F4/80 (macrophage invasion),
Figure 1. Effect of Trichostatin A (TSA) on the expression of fibrogenic components in cultured human subconjunctival fibroblasts. A: Real-
time RT–PCR showed that 10 nM of TSA suppressed mRNA expression of transforming growth factor β1 (TGFβ1) and collagen I a1 chain.
B: TSA reduced the production of TGFβ1 at the protein level in the presence of exogenous TGFβ1. *p<0.05. C: Immunocytochemistry showed
reduction of protein expression of collagen type I in the cell cytoplasm and deposition of fibronectin in the cell layer by adding concentrations
of TSA. Bar, 100 µm. D: Effects of TSA on fibroblast migration were evaluated by scratch assay. A liner a defect was produced in a fibroblast
monolayer. The cells migrated into the defect and the defect was closed in 36 h in the control culture. TSA retarded migration of fibroblasts
into the defect. Bar, 200 µm.
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PCR. The animals were sacrificed at day-5 or day-10 and their
corneas  were  excised.  The  total  RNA  extraction  was
performed using two corneal tissues for one reaction. Real-
time  RT–PCRs  were  performed  following  the  methods
reported earlier [16,20,27]. The real-time RT-PCR method
Figure 2. Effect of Trichostatin A (TSA) on expression of transforming growth factor β1 (TGFβ1)-related signal transduction in cultured
human subconjunctival fibroblasts. A: western blotting indicates that at 2 h post-TGFβ1 addition TSA at concentrations of 200 nM faintly
reduced the level of phosphorylated Smad2 (pSamd2) as compared with the phosphorylation level at 1 h post-TGFβ1 addition, while the cells
maintained a similar level of phosphorylation of Smad2 until 2 h in the absence of TSA. TSA at a concentration of 500 nM obviously reduced
its  phosphorylation  level  at  2  h.  Adding  TSA  upregulated  the  expression  of  Smad7  and  TGIF  in  a  dose-dependent  manner.  B:
Immunocytochemistry also showed that TSA suppressed nuclear translocation of pSmad2. In the absence of TSA pSmad2 was detected in
cell nuclei at 0.5 and 1.0 h post-TGFβ1 addition. With TSA at a concentration of 10 nM pSmad2 was detected in the nuclei after 0.5 h. TSA
at the concentrations of 200 and 500 nM abolished its nuclear expression.
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Kit and the Applied Biosystems Prism 7300 (P-E Applied
Biosystems, Foster City, CA) was employed.
RESULTS
Effects  of  TSA  on  fibrogenic  gene  expression  of
subconjunctival fibroblasts: Real-time RT–PCR showed TSA
suppressed mRNA expression of TGFβ1 and collagen Iα1 in
fibroblast culture (Figure 1A). ELISA also showed that TSA
reduces  the  secretion  of  TGFβ1  protein  (Figure  1B).
Immunohistochemistry  showed  that  TSA  decreased  the
degree of staining for type I collagen in the cell cytoplasm as
well as deposition of fibronectin EDA domain in the cell layer
(Figure 1C).
Fibroblast proliferation and migration: Addition of TSA to
culture suppressed cell migration in a dose-dependent manner
is determined by scratch assay (Figure 1D). Migration of cells
into the defect was impaired relatively more at higher doses
compared to that at lower doses of TSA.
Effects of TSA on TGFβ1 signal transduction: As for the
TGFβ1/Smad signal, the level of phospho-Smad2 2 h post-
TGFβ1 addition TSA at a concentration of 200 nM faintly
reduced compared with the phosphorylation level 1 h post-
TGFβ1 addition. While the cells maintained a similar level of
phosphorylation of Smad2 until 2 h in the absence of TSA.
TSA at a concentration of 500 nM substantially reduced the
Smad2 phosphorylation level at 2 h. The addition of TSA to
cultures upregulated the expression of Smad7 and TGIF in a
dose-dependent manner (Figure 2A).
Immunocytochemistry also showed that TSA suppressed
nuclear translocation of pSmad2 (Figure 2B). In the absence
of TSA, pSmad2 was detected in cell nuclei at 0.5 and 1.0 h
post-TGFβ1 addition (Figure 2B); whereas in the presence of
TSA (10 nM), phospho-Smad2 was detected in the nuclei after
0.5 h. TSA at the concentrations of 200 and 500 nM abolished
pSmad2 nuclear expression (Figure 2B).
Cytokine expression by macrophages: The RT–PCR studies
demonstrated that macrophages exposed to 10 nM of TSA for
24 h significantly suppressed levels of TGFβ1 and VEGF
mRNA expression (Figure 3). The continuous exposure of
TSA  to  other  tested  higher  concentrations  showed  more
pronounced effects (data not shown).
In vitro neovascularization: To determine the effects of TSA
on corneal neovascularization, HUVEC cells were grown on
the  fibroblast  feeder  layer.  HUVECs  form  CD31-positive
tube-like structures on a fibroblast feeder layer in the presence
of VEGF. When evaluated by the measurement of total length
and the number of the branching points of vessel-like tubes
formed  by  HUVECs,  TSA  at  the  tested  concentrations
inhibited elongation of CD31-labeled tube-like structures in a
dose-dependent manner (Figure 4). All of the three tested
doses (10, 200, and 500 nM) of TSA significantly inhibited
bifurcation and branching of the tubes. Except for the10 nM
dose  of  TSA,  all  other  tested  doses  similarly  showed
significant reduction in the length and density of these tube-
like structures.
Evaluation of the effect of systemic TSA on ocular surface
inflammation and fibrosis caused by an alkali burn in mice:
An  alkali  burn  of  the  ocular  surface  resulted  in  corneal
Figure 3. Effects of TSA on cytokine expression in cultured macrophages. Expression of transforming growth factor β1 (TGFβ1) and vascular
endothelial growth factor (VEGF) mRNAs in cultured macrophages incubated for 24 h in the presence or absence of 10 nM TSA as evaluated
by real-time RT–PCR. Expressions of TGFβ1 and VEGF were markedly suppressed by continuous exposure to TSA. ***p<0.01.
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scarring (opacification) and neovascularization in the later
phase (day 10; Figure 5A). Systemic TSA treatment (600 µg/
kg/day; i.p.) given to mice markedly reduced the incidence of
epithelial defect at day-10 in the post-alkali burn eyes as
demonstrated by the χ2-square test (Figure 5B).
Histological  results  coincided  with  the  findings  from
ocular surface observation. H&E staining showed that alkali
exposure  induced  inflammation  with  epithelial  defects  in
stroma. Increased cellularity, presumably inflammatory cells,
was seen in control corneal sections (Figure 5C; left panels)
compared to that in TSA-treated corneal sections (Figure 5C;
right panels). Immunohistochemistry also showed an irregular
accumulation of type IV collagen α1 peptide in the stroma
beneath the healing epithelium in a control animal, while it
was not detected in the well healed epithelium of a TSA group
cornea (Figure 5D).
Real-time RT–PCR showed that systemic TSA treatment
significantly suppressed mRNA expression levels of F4/80,
αSMA,  TGFβ1,  and  collagen  type-I  in  the  healing  alkali-
burned mouse corneas on day 5 or day 10 (Figure 6A-D).
Immunohistochemistry  analysis  of  corneal  tissue  sections
showed  fewer  myofibroblasts  and  macrophages  in  TSA-
treated (Figure 6E; right panels) healing alkali-burned mouse
corneas than the control corneas (Figure 6E; left panels).
DISCUSSION
In the present study we showed that TSA exhibited anti-
inflammatory as well as anti-profibrogenic activity in cultured
macrophages or human subconjunctival fibroblasts. The TSA
treatment suppressed the expression of TGFβ1 and VEGF in
cultured macrophages and TGFβ1 and collagen type I as well
as expression of αSMA, the marker for a myofibroblast, in
cultured subconjunctival fibroblasts. We hypothesize that the
suppression  of  TGFβ1  expression  by  TSA  is  due  to  the
reduction of collagen in TSA-culture. Reduced deposition of
fibronectin in cell layers might be caused by reduced collagen
accumulation that reportedly forms a scaffold for fibronectin
deposition in cell layer. Nonetheless, the addition of TSA did
not affect cell proliferation (data not shown). Consistent with
the data from other studies, our findings indicate involvement
of epigenetic histone modifications in the expression of pro-
inflammatory  or  profibrogenic  components  in  the  cornea.
Similar in vitro findings of antifibrogenic effects of TSA were
reported in cultured rat mesangial cells [28].
Several  possible  mechanisms  for  TSA-mediated
inhibition of proinflammatory or profibrogenic response have
been  postulated.  TSA  or  TSA-induced  gene  products  are
known to interfere with the signaling cascade(s) involved in
cell proinflammatory and/or profibrogenic reaction. Binding
of TGFβ to its receptor phosphorylates Smad2/3 and activates
Figure 4. Effects of Trichostatin A (TSA) on in vitro neovascularization were evaluated by a co-culture model of human umbilical vein
endothelial cells (HUVECs) and fibroblasts. A: HUVECs form CD31-positive tube-like structure on a fibroblast feeder layer in the presence
of vascular endothelial growth factor. TSA seems to inhibit formation of CD31-labeled tube-like tissues. Bar, 50 mm. B: When evaluated by
the measurement of total length and the number of the branching points of vessel-like tubes formed by HUVECs, TSA at the concentrations
inhibited elongation of CD31-labeled tube like formation by HUVECs in a dose-dependent manner. *, **, and *** represent p<0.05, 0.01,
and 0.005, respectively.
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then  form  a  complex  with  Smad4  and  translocate  to  the
nucleus [29,30]. Together with Smad co-activator(s) or co-
repressor(s),  the  Smad2/3/4  complexes  regulate  the
expression  of  several  profibrogenic  genes.  In  the  present
study,  we  examined  expression  patterns  of  Smad-related
molecules  by  western  blotting  and  immunocytochemistry.
The results of our study show that TSA upregulates Smad7
(an inhibitory Smad that blocks phosphorylation of Smad2/3)
and TGIF (a co-repressor of Smad-dependent gene expression
that  directly  associates  with  Smad  proteins)  and  inhibits
Smad-mediated  transcriptional  activation  in  cultured
subconjunctival fibroblasts.
Immunocytochemistry showed that even a low TSA dose
(10 nM) suppressed translocation of pSmad2 to the nuclei
whereas high doses of TSA (200 and 500 nM) eliminated the
pSmad2 signal from the cell nuclei as no pSmad2 expression
was detected in the cell nuclei at these 2 TSA doses. Western
blot analysis of these experiments was also in agreement with
the immunocytochemistry data, except the 200 nM dose of
TSA. Western blot analysis of samples treated with 200 nM
TSA did not completely block phosphorylation of Smad2;
instead, it faintly reduced the pSmad2 levels at 2 h post-
TGFβ1  addition  compared  to  the  Smad2  phosphorylation
level  noted  1  h  post-TGFβ1  addition.  The  levels  of
phosphorylation of Smad2 in control samples were about the
same at 1 and 2 h. The discrepancy noted for the 200 nM TSA
concentration could not be completely explained at this time.
We speculate that this might be due to Smad2 import in the
nuclei as TSA not only reduces the phosphorylation level of
Smad2 but also inhibits its import to the nuclei. Moreover, it
is also likely that upregulation of TGIF might have suppressed
the Smad-dependent gene expression at the gene promoter
level.
Tissue scarring is well characterized by the invasion of
inflammatory  cells  such  as  macrophages,  and  subsequent
generation of myofibroblasts that pose αSMA cytoskeletal
fibers from the fibroblasts. Expression of αSMA is regulated
by the gene promoter activity and extracellular scaffold. The
αSMA promoter is activated by the Smad2 but the appearance
Figure 5. Evaluation of the effect of systemic Trichostatin A (TSA) on ocular surface fibrosis model of an alkali burn in mice. A: An alkali
burn of the ocular surface resulted in epithelial defects, stromal scarring (opacification) and neovascularization on day 5 and day 10. Treatment
of the animals with systemic TSA, i.p., seemed to reduce the incidence of residual epithelial defects and stromal opacification. B: The incidence
of residual epithelial defects was significantly less ons day 10, but not on day 5, as evaluated using the χ2-square test (p<0.05). C: Histology
by hematoxylin and eosin staining shows that alkali exposure induced inflammation with epithelial defects in the stroma. More cellularity,
presumably due to inflammatory cells, was seen in control animals compared with that in TSA-treated mice on days 5 and 10. D: Irregular
accumulation of type VI collagen α1chain was detected (arrows) in the stroma beneath the healing epithelium in a control animal, while it
was not detected in the well healed epithelium of a cornea from the TSA group. Bar, 100 µm.
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myofibroblasts  depends  on  extracellular  deposition  of
fibronectin, especially ED-A type fibronectin [31]. Thus, we
postulate that suppression of myofibroblasts by TSA is due to
the suppression of Smad activity by the upregulation of Smad7
and  TGIF  and  inhibition  of  extracellular  deposition  of
fibronectin.
Our in vitro studies led us to hypothesize that systemic
administration  of  TSA  might  suppress  the  inflammatory
fibrogenic reaction in an alkali-burned cornea. To test this
hypothesis we conducted in vivo experiments using a mouse
cornea-alkali burn model. The intraperitoneal administration
of TSA was chosen over topical administration on the eye to
avoid washing TSA from the ocular surface by the tears.
However, therapeutic levels of TSA can be maintained in the
eyes of patients via topical application of TSA. The results of
histology,  real-time  RT–PCR,  and  immunohistochemistry
experiments suggest that systemic TSA treatment exhibits
therapeutic anti-inflammatory and antifibrogenic activities in
an alkali-burned mouse cornea. Administration of systemic
TSA treatment (i.p.) to the animals reduced the incidence of
epithelial defect(s) and stromal inflammation. Evaluation of
the  gene  expression  pattern  showed  that  systemic  TSA
inhibited the appearance of myofibroblasts, as detected by
αSMA expression and macrophage invasion, as indicated by
the expression of F4/80. Such phenomenon could explain the
suppression  of  mRNA  expression  of  TGFβ1,  presumably
expressed mainly in macrophages, and collagen I, a major
fibrogenic product expressed by myofibroblasts, in a TSA-
treated  healing  cornea.  Besides  histology,  epithelial
regeneration was further evaluated by immunodetection of
type  IV  collagen  α1  chain.  Normal  epithelial  basement
membrane of the cornea does not contain type IV collagen
α1 chain dissimilar to the usual basement membrane, while
this type of α chain appears in a newly regenerated immature
basement membrane in an injured cornea [32-34]. Thus, the
presence of α1chain of type IV collagen suggests unorganized
regeneration of the healing basement membrane of the corneal
Figure 6. Characterization of healing of an alkali-burned cornea treated with systemic Trichostatin A (TSA) by real-time reverse transcription
polymerase chain reaction (real-time RT–PCR) and immunohistochemistry. Real-time RT–PCR showed that systemic TSA treatment
suppressed mRNA expression levels of a macrophage antigen, F4/80 (A), α-smooth muscle actin (αSMA; B), transforming growth factor β1
(TGFβ1; C) and collagen typeI (D) in a healing alkali-burned mouse cornea on day 5 and day 10. **p<0.01, *p<0.05. E: Immunohistochemistry
also showed fewew myofibroblasts and macrophages in a TSA-treated healing alkali-burned mouse cornea compared with those in control
mice. Bar, 100 µm.
Molecular Vision 2010; 16:2964-2973 <http://www.molvis.org/molvis/v16/a319> © 2010 Molecular Vision
2971epithelium.  In  the  present  study,  the  TSA-group  cornea
exhibited no immunolabeling of this type of α chain in the
epithelial  basement  membrane,  while  the  α1  chain  was
detected beneath the partially regenerated epithelium. This
finding  further  supports  the  acceleration  of  restoration  of
normal corneal structure following TSA administration.
Our data are consistent with the results of previously
published studies that demonstrated antifibrotic properties or
anti-Smad3-driven epithelial-mesenchymal transition of TSA
[13,35]. Similar in vivo findings showing that TSA suppresses
macrophage  invasion  and  local  finbrogenic  reaction  were
observed  in  an  animal  model  of  renal  fibrosis  [36].  Our
preliminary  experiment  showed  that  there  was  such  no
beneficial effect of daily TSA, i.p., on the healing process in
an  alkali-burned  mouse  cornea  at  1  month  post-alkali
treatment (data not shown). The exact reason why we did not
observe the efficacy in the present alkali-burn model is also
necessary further investigate whether this might be the case
in other animals as well. Nevertheless, the present findings
support the potential utility of the drug in treating human
cases.
In conclusion, TSA has great potential to be an effective
drug to treat inflammatory and fibrotic disorders in the ocular
surface among patients. Mechanism of action might include
suppression  of  cytokine  expression,  migration  of
macrophages, inhibition of TGFβ-driven fibroblast activation
and/or myofibroblast conversion. Further study is needed to
establish  the  clinical  utility  and  the  suitable  route(s)  of
administration of the drug for the treatment of ocular surface
inflammatory fibrogenic disorders.
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